I am a healthcare professional

Notice


Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.


Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.


By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.


Cookies


We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.


You can find out more about cookies by browsing our Privacy Policy.

 

For healthcare professionals in Another Country browse medically.roche.com.

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site

Non-Hodgkin Lymphoma

What's new

Sign up or login to unlock the full suite of MEDICALLY features

Dec 9 / Roche and Genentech
Englumafusp Alfa (CD19-4-1BBL) Combined with Glofitamab▼ is Safe and Efficacious in Patients with R/R B-NHL: Extended Follow-Up Analysis of the Dose-Escalation Part of Phase 1 Trial BP41072
BP41072 is a Phase Ib study combining englumafusp alfa with glofitamab▼ in patients with R/R NHL. Updated safety and efficacy data from the dose-escalation part of the study are presented.

Sign up or login to unlock the full suite of MEDICALLY features

Dec 8 / Roche and Genentech
BP43131, a Phase 1 Dose Escalation Study: CD19 Targeted CD28 Costimulatory Agonist Antibody (RO7443904) Combined with Glofitamab▼ Shows Promising Efficacy in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma
BP43131 is a Phase I study combining RO7443904 with glofitamab▼ in patients with R/R NHL. Safety, efficacy, PK and PD data from the dose-escalation part of the study will be presented.

Sign up or login to unlock the full suite of MEDICALLY features

Dec 8 / Roche and Genentech
CD19-CD28 (RO7443904) Combination with Glofitamab▼ Enhances T-Cell Proliferation and Effector Function in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma
BP43131 is a Phase I dose-escalation study evaluating RO7443904 in combination with glofitamab▼ in patients with R/R NHL. Biomarker analyses demonstrating mechanism of action, dose relationship, and features associated with clinical response are reported.

Ask a question or share feedback